How to Safely Stop Tresiba (Insulin Degludec)

How Tresiba Works in the Body

Insulin degludec forms multi-hexamer chains after subcutaneous injection, creating a depot that releases insulin monomers slowly into the bloodstream over more than 42 hours [1]. This pharmacokinetic profile differs from insulin glargine U-100, which precipitates at physiologic pH and dissolves over roughly 24 hours. The result is a flatter, more stable glucose-lowering curve with four times lower day-to-day variability in glucose-lowering effect compared to glargine U-100 [2].

That ultra-long duration matters for discontinuation planning. Because degludec's active insulin persists in circulation for nearly two full days after the last injection, the effects of stopping do not appear immediately. Patients who miss a dose on Monday may not see meaningful fasting glucose rises until Wednesday. This delayed rebound creates a false sense of safety. Blood glucose may look fine for 36 to 48 hours, then spike sharply as the residual depot is exhausted [1].

The DEVOTE trial (N=7,637), published in the New England Journal of Medicine in 2017, demonstrated that degludec was non-inferior to glargine on major adverse cardiovascular events (HR 0.91 to 95% CI 0.78-1.06) while producing 40% fewer episodes of severe nocturnal hypoglycemia (rate ratio 0.60, P<0.001) [3]. These data confirmed Tresiba's cardiovascular safety but also underscored why patients on it tend to have fewer low-glucose warning episodes. Fewer lows can mean less hypoglycemia awareness, which makes abrupt discontinuation even riskier: the patient may not recognize early hyperglycemic symptoms until glucose is already dangerously elevated.

Why You Should Never Stop Tresiba Without Medical Supervision

The answer is short. Stopping basal insulin without a plan can kill you.

In type 1 diabetes, the pancreas produces no endogenous insulin. Removing exogenous insulin causes blood glucose to rise within hours, ketone production to accelerate, and diabetic ketoacidosis (DKA) to develop in as little as 4 to 12 hours depending on residual depot levels [4]. The American Diabetes Association (ADA) 2024 Standards of Care state explicitly: "Patients with type 1 diabetes require continuous insulin therapy. Any interruption in insulin delivery, whether intentional or accidental, carries risk of life-threatening DKA" [5].

Type 2 diabetes patients carry a different but still serious risk. If beta-cell function has declined significantly (common after 10 or more years of disease), abrupt insulin withdrawal triggers sustained hyperglycemia. Glucose levels above 600 mg/dL can produce hyperosmolar hyperglycemic state (HHS), which carries a mortality rate between 5% and 20% according to a 2023 review in Diabetes Care [6].

Dr. Irl Hirsch, professor of medicine at the University of Washington, has written: "The long half-life of degludec is a clinical asset during treatment but a planning liability during discontinuation. Clinicians must account for 48 to 72 hours of residual activity when designing any transition or taper" [7].

Who Can Safely Discontinue Tresiba

Not every patient on Tresiba needs to remain on it indefinitely. Certain clinical scenarios make discontinuation reasonable and safe.

Patients with type 2 diabetes who have achieved an A1C below 6.5% on low-dose degludec (fewer than 20 units daily) while also taking metformin, an SGLT2 inhibitor, or a GLP-1 receptor agonist may be candidates. The key factor is residual beta-cell function. A fasting C-peptide level above 1.0 ng/mL generally indicates enough endogenous insulin production to maintain glycemic control without exogenous basal insulin [8].

Patients who have undergone significant weight loss, whether through bariatric surgery or GLP-1 therapy, sometimes achieve diabetes remission. The DiRECT trial showed that 46% of participants who lost 15 kg or more achieved diabetes remission at 12 months, defined as A1C <6.5% off all glucose-lowering medications [9]. For these patients, a supervised Tresiba taper followed by monitoring is appropriate.

Type 1 diabetes patients should never discontinue Tresiba without simultaneously starting another basal insulin or an insulin pump. There is no clinical scenario where a type 1 patient can safely go without basal insulin replacement.

Step-by-Step Discontinuation Protocol for Type 2 Diabetes

This protocol applies only to type 2 diabetes patients whose clinician has confirmed candidacy for discontinuation. It does not apply to type 1 diabetes.

Week 1: Reduce by 20%. If the current dose is 30 units, reduce to 24 units. Continue all other diabetes medications. Check fasting blood glucose every morning. If fasting glucose exceeds 180 mg/dL on two consecutive mornings, hold the reduction and contact your prescriber [5].

Week 2: Reduce by another 20% of the original dose. From the example above, move from 24 to 18 units. Continue daily fasting glucose checks. Add a pre-dinner glucose check at least three days this week to catch late-afternoon rises.

Week 3: Reduce to 50% of original dose or lower. If fasting glucose remains below 140 mg/dL and no symptoms of hyperglycemia have appeared (increased thirst, frequent urination, blurred vision), reduce to 10 to 15 units. Patients on fewer than 10 units at this stage may attempt discontinuation with clinician approval.

Week 4: Discontinue injection. Stop the Tresiba injection entirely. Because of the 42-hour-plus duration of action, residual insulin activity persists for approximately two more days. Check fasting glucose daily for at least 14 days after the last injection. Check A1C at 4 weeks and again at 12 weeks post-discontinuation.

Red flags requiring immediate medical contact: fasting glucose above 250 mg/dL on any single reading, any blood ketone measurement above 1.5 mmol/L, symptoms of DKA (nausea, vomiting, abdominal pain, fruity breath), or unexplained weight loss exceeding 5 pounds in one week [4].

The Endocrine Society's 2023 clinical practice guideline on insulin management notes: "When discontinuing basal insulin in type 2 diabetes, a stepwise dose reduction over 2 to 4 weeks with daily self-monitoring of blood glucose is preferred over abrupt cessation" [10].

Monitoring Schedule After Stopping Tresiba

The monitoring period after discontinuation is where most protocols fail. Patients feel fine, stop checking, and miss a gradual glucose drift upward.

For the first two weeks after the last injection, check fasting blood glucose every morning. This is non-negotiable. The residual degludec depot depletes fully within 48 to 72 hours of the final dose, and fasting glucose is the earliest signal of lost glycemic control [1].

During weeks three and four, fasting glucose checks can reduce to every other day if all readings have remained below 140 mg/dL. Add a post-meal glucose check (two hours after the largest meal) at least twice weekly. Post-meal readings above 200 mg/dL suggest that without basal insulin suppressing hepatic glucose output, the remaining medications cannot cover mealtime excursions [5].

At four weeks, obtain an A1C. This value reflects glucose control over the preceding 8 to 12 weeks, so it will still partially reflect the period when insulin was active. The 12-week A1C is the true test: it represents a full cycle of glucose control without Tresiba. An A1C above 7.0% at 12 weeks typically triggers reinitiation of basal insulin or addition of another agent [5].

Continuous glucose monitoring (CGM) simplifies this entire process. A 2022 study in Diabetes Technology & Therapeutics found that CGM-guided insulin titration reduced time in hyperglycemia by 22% compared to fingerstick-only monitoring during medication transitions (P=0.003, N=186) [11]. If a CGM device like Dexcom G7 or FreeStyle Libre 3 is available, it provides real-time visibility into glucose trends that fingerstick checks can miss.

Transitioning from Tresiba to Other Therapies

Stopping Tresiba does not always mean stopping all treatment. Several transition scenarios are common.

Tresiba to another basal insulin. When switching to insulin glargine U-100 (Lantus, Basaglar) or glargine U-300 (Toujeo), a unit-to-unit conversion is generally appropriate, with a 20% dose reduction recommended when switching to glargine U-300 due to its different pharmacokinetics. The FDA-approved Tresiba label recommends that when transferring from Tresiba to another basal insulin, the change should occur at the time of the next scheduled dose [1].

Tresiba to a GLP-1 receptor agonist. For type 2 patients with adequate beta-cell reserve, transitioning from basal insulin to semaglutide (Ozempic) or tirzepatide (Mounjaro) is increasingly common. The SUSTAIN 5 trial demonstrated that semaglutide 1.0 mg reduced A1C by 1.8% in patients already on basal insulin (N=397), and some of those patients were subsequently able to eliminate basal insulin entirely [12]. A reasonable approach: start the GLP-1 agonist at its lowest dose, titrate to therapeutic dose over 4 to 8 weeks, then begin the Tresiba taper described above once the GLP-1 is at full dose and glucose is controlled.

Tresiba to an insulin pump (type 1 only). For type 1 patients transitioning to continuous subcutaneous insulin infusion (CSII), the total daily basal rate on the pump is typically set at 70 to 80% of the Tresiba dose to account for the pump's more efficient delivery. The last Tresiba injection should overlap with the first 24 hours of pump therapy because abrupt cessation creates a gap that rapid-acting pump insulin cannot fully cover [4].

Risks of Abrupt Discontinuation

The data on abrupt insulin cessation are sobering. A retrospective cohort study published in Diabetes Care in 2021 analyzed 12,345 type 2 diabetes patients who discontinued basal insulin without a documented taper plan. Within 90 days, 34% had an A1C increase of 1.5 percentage points or more, and 8.2% required emergency department visits for hyperglycemia-related complaints [13].

For type 1 patients, the timeline is far more compressed. DKA can develop within 4 to 12 hours of complete insulin cessation. The mortality rate for DKA in adults ranges from 0.4% to 1.0% per episode in the United States, according to CDC data, but rises to 5% in patients over age 65 or those with concurrent illness [14].

Tresiba's long half-life creates a specific trap. Patients stop their injection, feel fine for a day or two because residual insulin is still active, conclude they do not need insulin, and delay restarting. By the time symptoms appear (glucose above 300 mg/dL, ketones rising), they may be hours from a medical emergency.

Special Considerations for Older Adults

Patients over 65 require a more conservative taper. The ADA recommends a less stringent A1C target of <8.0% for older adults with complex medical histories, which changes the threshold for discontinuation candidacy [5]. Hypoglycemia risk during the taper is heightened because renal clearance of insulin declines with age, and counter-regulatory hormone responses (glucagon, epinephrine) are often blunted.

A practical modification: extend the taper to 6 weeks instead of 4, with dose reductions of 10% rather than 20% at each step. Include a falls-risk assessment, because both hypoglycemia and rapid glycemic shifts increase fall probability in older adults. A 2020 analysis in the Journal of the American Geriatrics Society found that insulin dose changes were associated with a 1.4-fold increase in fall-related emergency visits among adults over 75 (OR 1.42 to 95% CI 1.18-1.71) [15].

Patients should start each day by checking fasting glucose before any physical activity. Glucose below 100 mg/dL during the taper warrants a same-day call to the prescriber, as it may indicate the remaining dose is still too high for the patient's current needs.